에 대한 최신 뉴스 Molina Healthcare (NYSE:MOH) 주식

Molina Healthcare

Molina Healthcare Inc offers healthcare plans focused on Medicaid-related solutions for low-income families and individuals. Its health plans are operated by a network of subsidiaries, each of which is licensed as a health maintenance organization (HMO). It has four segments: Medicaid, Medicare, Marketplace and Others. The Medicaid, Medicare, and Marketplace segments represent the government-funded or sponsored programs under which it offers managed healthcare services. The Other segment, which is insignificant to its consolidated results of operations, includes long-term services and supports consultative services in Wisconsin. It generates majority revenue from Medicaid segment.

Equities

News

Global

Markets

ACIC

BABA

BIDU

FOUR

2008년 금융 위기를 예측한 것으로 유명한 헤지펀드 매니저인 마이클 버리(Michael Burry)는 2008년 금융 위기를 예측한 것으로 유명한 헤지펀드 매니저로, 최근 중국 기술 기업에 대한 노출을 크게 늘렸으며 동시에 잠재적 하방 위험에 대한 보호 조치를 시행했다고 규제 공시에서 밝혔다.

&#39;빅 쇼트&#39; 투자자 마이클 버리, 중국 기술주에 베팅 확대하면서 보호 헤지 추가

Large Cap

Movers

Trading Ideas

CPRI

GRAB

MSTR

TSLA

이들 10개 대형주는 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요? 1. 테슬라(NASDAQ:TSLA)의 주식은 실적 호조와 전반적인 시장 강세로 인해 21.97% 상승했다.

테슬라와 리 오토는 지난주 최고 성과를 보여준 10개 대형주 중 일부 (10월 21일-10월 25일)

Short Sellers

ASML

streetTRACKS Dow Jones U.S. Large Cap Value Index Fund

ERIE

KLAC

LRCX

Citigourp Global Markets 2% Protected Notes Linked To The Djia

이들 10개 대형주는 지난주 최악의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요? 1. 니오(NYSE:NIO)의 주식이 지난주 16.35% 하락했다. 이는 미국에 상장된 중국 주식들이 중국의 9월 수출이 예상치를 밑돌면서 하락한 후 발생한 일이다. 중국 경기 부양책에 대한 불확실성도 최근 주식에 악영향을 미쳤다.

니오, ASML 및 CVS 헬스는 지난주 최악의 성과를 보인 10개 대형주 중 일부 (10월 14일-18일)

Molina Healthcare Inc

MOTOR OIL HELLAS CORINTH by Motor Oil (Hellas) Corinth Refineries S.A.

Motor Oil (Hellas) Corinth Refineries SA

MOTOR OIL HELLAS UNSP/ADR by Motor Oil (Hellas) Corinth Refineries S.A.

Collaborative Investment Series Trust Mohr Growth ETF

Mohawk Industries Inc

Robert F. Kennedy Jr., President Donald Trump's pick for health secretary, addressed a wide range of medical-related topics on Wednesday during a confirmation hearing with <a href="https://www.benzinga.com/25/01/43306674/trumps-hhs-pick-robert-kennedy-jr-begins-senate-confirmation-hearings">the Senate Finance Committee.</a>
While Kennedy&#8217;s tone in each back-and-forth varied, depending on the senator, it was evident that Kennedy&#8217;s role in the new administration would have a tremendous impact on both pharma and insurance stocks.
<h3 class="wp-block-heading">Drug Price Negotiation</h3>
During one exchange about the high cost of drugs with Senator Catherine Cortez Masto (D-NV), Kennedy said: "Senator, my understanding is that the White House issued an executive order, I believe today, supporting the drug negotiations under the I.R.A. President Trump was very aggressive during his first term about negotiating drug prices."
In reality, Trump has not signed an executive order on the topic since he was sworn into office. A Wednesday news <a href="https://www.cms.gov/newsroom/press-releases/cms-statement-lowering-cost-prescription-drugs" target="_blank" rel="noreferrer noopener">release</a> from the Centers for Medicare and Medicaid Services said that lowering the cost of prescription drugs for Americans &#8220;a top priority&#8221; for the Trump administration and that he would work to improve the transparency of the negotiation process.
Perhaps Kennedy was recalling Trump&#8217;s first term. In 2020, then-45th President Trump <a href="https://www.benzinga.com/general/biotech/20/09/17482940/trump-signs-executive-order-to-lower-us-drug-prices-after-negotiations-with-drugmakers-fail">signed an executive order</a> on U.S. Medicare drug prices intending to reduce costs. Industry leaders, including Pfizer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) CEO Albert Bourla, criticized the move. Pfizer was seeking regulatory approval to expand its late-stage vaccine trial at the time.
If Trump signs such an order, it would be a rare show of support from his camp for a Biden-era initiative. In addition to Pfizer, it would also impact major companies like Bristol Myers Squibb, Eli Lilly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>), Merck &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>), AstraZeneca (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>), Novartis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>) and AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>).
Last month, the Biden administration <a href="https://www.benzinga.com/25/01/43062779/popular-ozempic-wegovy-selected-for-next-round-of-medicare-drug-price-negotiations">identified the next 15 drugs</a> as subject to negotiation. The list included Ozempic and Wegovy — two expensive drugs for diabetes and obesity owned by Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>).
See Also: <a href="https://www.benzinga.com/25/01/43306674/trumps-hhs-pick-robert-kennedy-jr-begins-senate-confirmation-hearings">RFK Jr. Is A &#8216;Predator&#8217; Unfit For Office, Caroline Kennedy Says </a>
<h3 class="wp-block-heading">Insurance Providers</h3>
According to the <a href="https://www.nytimes.com/live/2025/01/29/us/rfk-jr-health-senate-hearing">New York Times</a>, Kennedy wasn&#8217;t exactly familiar with Medicare and Medicaid, but expressed support for Medicare Advantage, where private insurers provide coverage for elderly Americans.
Kennedy also called out what he considered to be &#8220;rapacious behavior by insurance companies." He even suggested he would support some of the efforts undertaken during the Biden administration to crack down on abusive tactics like denying care and overcharging the government.
Traders would be wise to keep an eye on how insurance stocks — especially those tied to Medicaid and Medicare providers — react if Kennedy is sworn in. The major players in this space include: 
UnitedHealth Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), the largest Medicare Advantage insurer in the U.S.; Centene Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>); Elevance Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELV#NYSE">ELV</a>), one of the largest Medicaid managed care organizations; Humana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>); CVS Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>); Molina Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>); and Cigna (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>).
What&#8217;s Next: Kennedy seeks to be Secretary of Health and Human Services — a position that would put him in charge of the health of the American people.
The title also puts him in charge of the Food and Drug Administration, the National Institutes of Health and the Centers for Disease Control and Prevention.
He will appear before the Senate Committee on Health, Education Labor and Pensions on Thursday.
Now Read:
<ul>
<li><a href="https://www.benzinga.com/news/25/01/43216758/well-go-as-far-as-im-allowed-trumps-plan-with-immigrants-starts-with-1-million-deportations" target="_blank" rel="noreferrer noopener">‘We'll Go As Far As I'm Allowed': Trump's Plan With Immigrants Starts With 1 Million Deportations</a></li>
</ul>
Image: Shutterstock

Health Care

Politics

Insurance

ABBV

RFK Jr. And Big Pharma: Health Secretary Hopeful Answers Pointed Questions On Drugs, Insurance, Trump Exec Orders

Molina Healthcare's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>) short percent of float has risen 5.26% since its last report. The company recently reported that it has 1.10 million shares sold short, which is 2.2% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.92 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Molina Healthcare Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1737998123_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Molina Healthcare has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Molina Healthcare's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Molina Healthcare's peer group average for short interest as a percentage of float is 5.45%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Ideas

Peering Into Molina Healthcare's Recent Short Interest

NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NRXS#NYSE">NRXS</a>), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, today announced medical policy coverage for Percutaneous Electrical Nerve Field Stimulation (PENFS), with Molina Healthcare. Molina, with over 40 years in operation, has approximately 5.1 million members across 13 states.
NeurAxis' PENFS technology, IB-Stim, is FDA-cleared for functional abdominal pain associated with irritable bowel syndrome (IBS) in adolescents 8-21 years old. IB-Stim is a non-surgical device that sends gentle electrical impulses into cranial nerve bundles in the ear. There are currently no FDA-approved drug therapies for children with abdominal pain-related disorders of the gut-brain interaction. Off label pharmacologic treatments can often have serious side effects, and most lack scientific evidence of efficacy.

NRXS

NeurAxis Announces Molina Healthcare Coverage For PENFS Therapy IB-Stim, FDA-Cleared For Treating Abdominal Pain In IBS Adolescents

Molina Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>) has outperformed the market over the past 20 years by 3.06% on an annualized basis producing an average annual return of 11.42%. Currently, Molina Healthcare has a market capitalization of $16.82 billion. 
Buying $100 In MOH: If an investor had bought $100 of MOH stock 20 years ago, it would be worth $869.74 today based on a price of $294.03 for MOH at the time of writing.
<h3>Molina Healthcare's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736896508_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Molina Healthcare Stock In The Last 20 Years

WIIM

Shares of health insurers are trading higher after The Centers for Medicare & Medicaid Services proposed a rise to Medicare Advantage payments.

Truist Securities analyst David Macdonald maintains Molina Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>) with a Buy and lowers the price target from $400 to $370.

Price Target

Analyst Ratings

Truist Securities Maintains Buy on Molina Healthcare, Lowers Price Target to $370

A notable insider purchase on January 2, was reported by Daniel Cooperman, Director at Molina Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>), based on the most recent SEC filing.
What Happened: Cooperman's recent purchase of 189 shares of Molina Healthcare, disclosed in a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0001179929/000117992925000010//Archives/edgar/data/1179929/000117992925000010/0001179929-25-000010-index.htm">U.S. Securities and Exchange Commission</a> on Thursday, reflects confidence in the company's potential. The total transaction value is $55,008.
The latest market snapshot at Friday morning reveals Molina Healthcare shares up by 0.37%, trading at $288.29.
<h3>About Molina Healthcare</h3>
Molina Healthcare Inc offers healthcare plans focused on Medicaid-related solutions for low-income families and individuals. Its health plans are operated by a network of subsidiaries, each of which is licensed as a health maintenance organization (HMO). It has four segments: Medicaid, Medicare, Marketplace and Others. The Medicaid, Medicare, and Marketplace segments represent the government-funded or sponsored programs under which it offers managed healthcare services. The Other segment, which is insignificant to its consolidated results of operations, includes long-term services and supports consultative services in Wisconsin. It generates majority revenue from Medicaid segment.
<h3>Molina Healthcare: Financial Performance Dissected</h3>
Revenue Growth: Molina Healthcare's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of 20.96%. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Insights into Profitability:
<ul>
<li>
Gross Margin: The company faces challenges with a low gross margin of 11.5%, suggesting potential difficulties in cost control and profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): Molina Healthcare's EPS outshines the industry average, indicating a strong bottom-line trend with a current EPS of 5.67.
</li>
</ul>
Debt Management: Molina Healthcare's debt-to-equity ratio stands notably higher than the industry average, reaching 0.53. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
Assessing Valuation Metrics:
<ul>
<li>
Price to Earnings (P/E) Ratio: Molina Healthcare's P/E ratio of 14.61 is below the industry average, suggesting the stock may be undervalued.
</li>
<li>
Price to Sales (P/S) Ratio: The current P/S ratio of 0.43 is below industry norms, suggesting potential undervaluation and presenting an investment opportunity for those considering sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): At 5.34, Molina Healthcare's EV/EBITDA ratio reflects a below-par valuation compared to industry averages signalling undervaluation
</li>
</ul>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>The Impact of Insider Transactions on Investments</h3>
Insider transactions shouldn't be used primarily to make an investing decision, however an insider transaction can be an important factor in the investing decision. 
Exploring the legal landscape, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as stipulated by Section 12 of the Securities Exchange Act of 1934. This encompasses executives in the c-suite and major hedge funds. These insiders are required to report their transactions through a Form 4 filing, which must be submitted within two business days of the transaction.
Highlighted by a company insider's new purchase, there's a positive anticipation for the stock to rise.
But, insider sells may not necessarily indicate a bearish view and can be motivated by various factors.
<h3>A Deep Dive into Insider Transaction Codes</h3>
When dissecting transactions, the focal point for <a href="https://www.benzinga.com/money/investing-tools">investors</a> is often those occurring in the open market, meticulously detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C indicates the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001179929">Check Out The Full List Of Molina Healthcare's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Trades

Eye On Growth: Daniel Cooperman Adds $55K Of Molina Healthcare Stock To Portfolio

A significant insider buy by Barbara L Brasier, Director at Molina Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>), was executed on January 2, and reported in the recent SEC filing.
What Happened: In a Form 4 filing on Thursday with the <a href="https://www.sec.gov/Archives/edgar/data/0001179929/000117992925000011//Archives/edgar/data/1179929/000117992925000011/0001179929-25-000011-index.htm">U.S. Securities and Exchange Commission</a>, it was disclosed that Brasier bought 189 shares of Molina Healthcare, amounting to a total of $55,008.
The latest update on Friday morning shows Molina Healthcare shares up by 0.37%, trading at $288.29.
<h3>Unveiling the Story Behind Molina Healthcare</h3>
Molina Healthcare Inc offers healthcare plans focused on Medicaid-related solutions for low-income families and individuals. Its health plans are operated by a network of subsidiaries, each of which is licensed as a health maintenance organization (HMO). It has four segments: Medicaid, Medicare, Marketplace and Others. The Medicaid, Medicare, and Marketplace segments represent the government-funded or sponsored programs under which it offers managed healthcare services. The Other segment, which is insignificant to its consolidated results of operations, includes long-term services and supports consultative services in Wisconsin. It generates majority revenue from Medicaid segment.
<h3>Unraveling the Financial Story of Molina Healthcare</h3>
Revenue Growth: Molina Healthcare's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 20.96%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Holistic Profitability Examination:
<ul>
<li>
Gross Margin: The company faces challenges with a low gross margin of 11.5%, suggesting potential difficulties in cost control and profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): Molina Healthcare's EPS outshines the industry average, indicating a strong bottom-line trend with a current EPS of 5.67.
</li>
</ul>
Debt Management: Molina Healthcare's debt-to-equity ratio is notably higher than the industry average. With a ratio of 0.53, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
Valuation Metrics:
<ul>
<li>
Price to Earnings (P/E) Ratio: The Price to Earnings ratio of 14.61 is lower than the industry average, indicating potential undervaluation for the stock.
</li>
<li>
Price to Sales (P/S) Ratio: The current P/S ratio of 0.43 is below industry norms, suggesting potential undervaluation and presenting an investment opportunity for those considering sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): Molina Healthcare's EV/EBITDA ratio at 5.34 suggests potential undervaluation, falling below industry averages.
</li>
</ul>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Why Pay Attention to Insider Transactions</h3>
Insightful as they may be, insider transactions should be considered alongside a thorough examination of other investment criteria.
In legal terms, an "insider" refers to any officer, director, or beneficial owner of more than ten percent of a company's equity securities registered under Section 12 of the Securities Exchange Act of 1934. This can include executives in the c-suite and large hedge funds. These insiders are required to let the public know of their transactions via a Form 4 filing, which must be filed within two business days of the transaction.
When a company insider makes a new purchase, that is an indication that they expect the stock to rise.
Insider sells, on the other hand, can be made for a variety of reasons, and may not necessarily mean that the seller thinks the stock will go down. 
<h3>Exploring Key Transaction Codes</h3>
Navigating through the landscape of transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> often prioritize those unfolding in the open market, precisely detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001179929">Check Out The Full List Of Molina Healthcare's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

55K Reasons To Be Bullish On Molina Healthcare Stock

A new SEC filing reveals that Richard M Schapiro, Board Member at Molina Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>), made a notable insider purchase on January 2,.
What Happened: Schapiro demonstrated confidence in Molina Healthcare by purchasing 189 shares, as reported in a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0001179929/000117992925000012//Archives/edgar/data/1179929/000117992925000012/0001179929-25-000012-index.htm">U.S. Securities and Exchange Commission</a> on Thursday. The total value of the transaction is $55,008.
In the Friday's morning session, Molina Healthcare's shares are currently trading at $288.29, experiencing a up of 0.37%.
<h3>Get to Know Molina Healthcare Better</h3>
Molina Healthcare Inc offers healthcare plans focused on Medicaid-related solutions for low-income families and individuals. Its health plans are operated by a network of subsidiaries, each of which is licensed as a health maintenance organization (HMO). It has four segments: Medicaid, Medicare, Marketplace and Others. The Medicaid, Medicare, and Marketplace segments represent the government-funded or sponsored programs under which it offers managed healthcare services. The Other segment, which is insignificant to its consolidated results of operations, includes long-term services and supports consultative services in Wisconsin. It generates majority revenue from Medicaid segment.
<h3>Molina Healthcare's Economic Impact: An Analysis</h3>
Revenue Growth: Molina Healthcare displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately 20.96%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Profitability Metrics:
<ul>
<li>
Gross Margin: The company shows a low gross margin of 11.5%, suggesting potential challenges in cost control and profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): Molina Healthcare's EPS is significantly higher than the industry average. The company demonstrates a robust bottom-line performance with a current EPS of 5.67.
</li>
</ul>
Debt Management: Molina Healthcare's debt-to-equity ratio surpasses industry norms, standing at 0.53. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
Valuation Metrics:
<ul>
<li>
Price to Earnings (P/E) Ratio: The Price to Earnings ratio of 14.61 is lower than the industry average, indicating potential undervaluation for the stock.
</li>
<li>
Price to Sales (P/S) Ratio: With a P/S ratio of 0.43 below industry standards, the stock shows potential undervaluation, making it an appealing investment option for those focusing on sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): With an EV/EBITDA ratio lower than industry benchmarks at 5.34, Molina Healthcare presents an attractive value opportunity.
</li>
</ul>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Why Insider Activity Matters in Finance</h3>
It's important to note that insider transactions alone should not dictate investment decisions, but they can provide valuable insights.
When discussing legal matters, the term "insider" refers to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as stipulated in Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and significant hedge funds. Such insiders are required to report their transactions through a Form 4 filing, which must be completed within two business days of the transaction.
A new purchase by a company insider is a indication that they anticipate the stock will rise.
On the other hand, insider sells may not necessarily indicate a bearish view and can be motivated by various factors.
<h3>Exploring Key Transaction Codes</h3>
For <a href="https://www.benzinga.com/money/investing-tools">investors</a>, a primary focus lies on transactions occurring in the open market, as indicated in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001179929">Check Out The Full List Of Molina Healthcare's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Noteworthy Insider Activity: Richard M Schapiro Invests $55K In Molina Healthcare Stock

On January 2, Richard C Zoretic, Board Member at Molina Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>) executed a significant insider buy, as disclosed in the latest SEC filing.
What Happened: Zoretic made a significant move by purchasing 189 shares of Molina Healthcare as reported in a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0001179929/000117992925000013//Archives/edgar/data/1179929/000117992925000013/0001179929-25-000013-index.htm">U.S. Securities and Exchange Commission</a>. The transaction's total worth stands at $55,008.
Monitoring the market, Molina Healthcare's shares up by 0.37% at $288.29 during Friday's morning.
<h3>Delving into Molina Healthcare's Background</h3>
Molina Healthcare Inc offers healthcare plans focused on Medicaid-related solutions for low-income families and individuals. Its health plans are operated by a network of subsidiaries, each of which is licensed as a health maintenance organization (HMO). It has four segments: Medicaid, Medicare, Marketplace and Others. The Medicaid, Medicare, and Marketplace segments represent the government-funded or sponsored programs under which it offers managed healthcare services. The Other segment, which is insignificant to its consolidated results of operations, includes long-term services and supports consultative services in Wisconsin. It generates majority revenue from Medicaid segment.
<h3>Understanding the Numbers: Molina Healthcare's Finances</h3>
Revenue Growth: Molina Healthcare displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately 20.96%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Insights into Profitability:
<ul>
<li>
Gross Margin: The company faces challenges with a low gross margin of 11.5%, suggesting potential difficulties in cost control and profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): Molina Healthcare's EPS is notably higher than the industry average. The company achieved a positive bottom-line trend with a current EPS of 5.67.
</li>
</ul>
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 0.53, caution is advised due to increased financial risk.
Financial Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: The P/E ratio of 14.61 is lower than the industry average, implying a discounted valuation for Molina Healthcare's stock.
</li>
<li>
Price to Sales (P/S) Ratio: With a P/S ratio of 0.43 below industry standards, the stock shows potential undervaluation, making it an appealing investment option for those focusing on sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): With an EV/EBITDA ratio lower than industry benchmarks at 5.34, Molina Healthcare presents an attractive value opportunity.
</li>
</ul>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Illuminating the Importance of Insider Transactions</h3>
Insider transactions shouldn't be used primarily to make an investing decision, however, they can be an important factor for an investor to consider.
Within the legal framework, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities as per Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and major hedge funds. These insiders are mandated to disclose their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
The initiation of a new purchase by a company insider serves as a strong indication that they expect the stock to rise.
However, insider sells may not always signal a bearish view and can be influenced by various factors.
<h3>Navigating the World of Insider Transaction Codes</h3>
Surveying the realm of stock transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> often give prominence to those unfolding in the open market, systematically detailed in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S signifies a sale. Transaction code C denotes the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001179929">Check Out The Full List Of Molina Healthcare's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Richard C Zoretic Of Molina Healthcare Shows Optimism, Buys $55K In Stock

A notable insider purchase on January 2, was reported by Ronna Romney, Director at Molina Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>), based on the most recent SEC filing.
What Happened: In a Form 4 filing on Thursday with the <a href="https://www.sec.gov/Archives/edgar/data/0001179929/000117992925000014//Archives/edgar/data/1179929/000117992925000014/0001179929-25-000014-index.htm">U.S. Securities and Exchange Commission</a>, it was disclosed that Romney bought 189 shares of Molina Healthcare, amounting to a total of $55,008.
Tracking the Friday's morning session, Molina Healthcare shares are trading at $288.29, showing a up of 0.37%.
<h3>Discovering Molina Healthcare: A Closer Look</h3>
Molina Healthcare Inc offers healthcare plans focused on Medicaid-related solutions for low-income families and individuals. Its health plans are operated by a network of subsidiaries, each of which is licensed as a health maintenance organization (HMO). It has four segments: Medicaid, Medicare, Marketplace and Others. The Medicaid, Medicare, and Marketplace segments represent the government-funded or sponsored programs under which it offers managed healthcare services. The Other segment, which is insignificant to its consolidated results of operations, includes long-term services and supports consultative services in Wisconsin. It generates majority revenue from Medicaid segment.
<h3>Molina Healthcare's Financial Performance</h3>
Revenue Growth: Molina Healthcare's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 20.96%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Profitability Metrics: Unlocking Value
<ul>
<li>
Gross Margin: The company faces challenges with a low gross margin of 11.5%, suggesting potential difficulties in cost control and profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): Molina Healthcare's EPS is significantly higher than the industry average. The company demonstrates a robust bottom-line performance with a current EPS of 5.67.
</li>
</ul>
Debt Management: Molina Healthcare's debt-to-equity ratio surpasses industry norms, standing at 0.53. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
Navigating Market Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: Molina Healthcare's P/E ratio of 14.61 is below the industry average, suggesting the stock may be undervalued.
</li>
<li>
Price to Sales (P/S) Ratio: The current P/S ratio of 0.43 is below industry norms, suggesting potential undervaluation and presenting an investment opportunity for those considering sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): With a below-average EV/EBITDA ratio of 5.34, Molina Healthcare presents an opportunity for value investors. This lower valuation may attract investors seeking undervalued opportunities.
</li>
</ul>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Understanding the Significance of Insider Transactions</h3>
Insider transactions, although significant, should be considered within the larger context of market analysis and trends.
In the realm of legality, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities under Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and major hedge funds. These insiders are required to disclose their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
Notably, when a company insider makes a new purchase, it is considered an indicator of their positive expectations for the stock.
Conversely, insider sells may not necessarily signal a bearish stance on the stock and can be motivated by various factors.
<h3>Important Transaction Codes</h3>
Surveying the realm of stock transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> often give prominence to those unfolding in the open market, systematically detailed in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S signifies a sale. Transaction code C denotes the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001179929">Check Out The Full List Of Molina Healthcare's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Confidence On Display: Ronna Romney Acquires $55K In Molina Healthcare Stock

Disclosed in the latest SEC filing, a significant insider purchase on January 2, involves Steven J Orlando, Director at Molina Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>).
What Happened: Orlando made a significant move by purchasing 189 shares of Molina Healthcare as reported in a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0001179929/000117992925000015//Archives/edgar/data/1179929/000117992925000015/0001179929-25-000015-index.htm">U.S. Securities and Exchange Commission</a>. The transaction's total worth stands at $55,008.
Molina Healthcare shares are trading down 0.0% at $287.24 at the time of this writing on Friday morning.
<h3>About Molina Healthcare</h3>
Molina Healthcare Inc offers healthcare plans focused on Medicaid-related solutions for low-income families and individuals. Its health plans are operated by a network of subsidiaries, each of which is licensed as a health maintenance organization (HMO). It has four segments: Medicaid, Medicare, Marketplace and Others. The Medicaid, Medicare, and Marketplace segments represent the government-funded or sponsored programs under which it offers managed healthcare services. The Other segment, which is insignificant to its consolidated results of operations, includes long-term services and supports consultative services in Wisconsin. It generates majority revenue from Medicaid segment.
<h3>Understanding the Numbers: Molina Healthcare's Finances</h3>
Revenue Growth: Over the 3 months period, Molina Healthcare showcased positive performance, achieving a revenue growth rate of 20.96% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Evaluating Earnings Performance:
<ul>
<li>
Gross Margin: The company shows a low gross margin of 11.5%, suggesting potential challenges in cost control and profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): Molina Healthcare's EPS is significantly higher than the industry average. The company demonstrates a robust bottom-line performance with a current EPS of 5.67.
</li>
</ul>
Debt Management: Molina Healthcare's debt-to-equity ratio is notably higher than the industry average. With a ratio of 0.53, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
Financial Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: The P/E ratio of 14.61 is lower than the industry average, implying a discounted valuation for Molina Healthcare's stock.
</li>
<li>
Price to Sales (P/S) Ratio: The Price to Sales ratio is 0.43, which is lower than the industry average. This suggests a possible undervaluation based on sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): With a below-average EV/EBITDA ratio of 5.34, Molina Healthcare presents an opportunity for value investors. This lower valuation may attract investors seeking undervalued opportunities.
</li>
</ul>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Why Pay Attention to Insider Transactions</h3>
Investors should view insider transactions as part of a multifaceted analysis and not rely solely on them for decision-making.
Considering the legal perspective, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, according to Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and major hedge funds. These insiders are mandated to disclose their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
Pointing towards optimism, a company insider's new purchase signals their positive anticipation for the stock to rise.
Nevertheless, insider sells may not necessarily indicate a bearish view and can be influenced by various factors.
<h3>Navigating the World of Insider Transaction Codes</h3>
Delving into transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> typically prioritize those unfolding in the open market, as precisely outlined in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001179929">Check Out The Full List Of Molina Healthcare's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Move: Steven J Orlando Invests $55K In Molina Healthcare Stock

On January 2, Dale B Wolf, Director at Molina Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>) executed a significant insider buy, as disclosed in the latest SEC filing.
What Happened: Wolf made a significant move by purchasing 189 shares of Molina Healthcare as reported in a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0001179929/000117992925000016//Archives/edgar/data/1179929/000117992925000016/0001179929-25-000016-index.htm">U.S. Securities and Exchange Commission</a>. The transaction's total worth stands at $55,008.
Molina Healthcare's shares are actively trading at $287.24, experiencing a down of 0.0% during Friday's morning session.
<h3>Unveiling the Story Behind Molina Healthcare</h3>
Molina Healthcare Inc offers healthcare plans focused on Medicaid-related solutions for low-income families and individuals. Its health plans are operated by a network of subsidiaries, each of which is licensed as a health maintenance organization (HMO). It has four segments: Medicaid, Medicare, Marketplace and Others. The Medicaid, Medicare, and Marketplace segments represent the government-funded or sponsored programs under which it offers managed healthcare services. The Other segment, which is insignificant to its consolidated results of operations, includes long-term services and supports consultative services in Wisconsin. It generates majority revenue from Medicaid segment.
<h3>Breaking Down Molina Healthcare's Financial Performance</h3>
Revenue Growth: Molina Healthcare's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 20.96%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Exploring Profitability:
<ul>
<li>
Gross Margin: The company shows a low gross margin of 11.5%, suggesting potential challenges in cost control and profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): Molina Healthcare's EPS is notably higher than the industry average. The company achieved a positive bottom-line trend with a current EPS of 5.67.
</li>
</ul>
Debt Management: Molina Healthcare's debt-to-equity ratio surpasses industry norms, standing at 0.53. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
Valuation Metrics: A Closer Look
<ul>
<li>
Price to Earnings (P/E) Ratio: With a lower-than-average P/E ratio of 14.61, the stock indicates an attractive valuation, potentially presenting a buying opportunity.
</li>
<li>
Price to Sales (P/S) Ratio: The P/S ratio of 0.43 is lower than the industry average, implying a discounted valuation for Molina Healthcare's stock in relation to sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): Molina Healthcare's EV/EBITDA ratio at 5.34 suggests potential undervaluation, falling below industry averages.
</li>
</ul>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Why Insider Transactions Are Key in Investment Decisions</h3>
Insider transactions should be considered alongside other factors when making investment decisions, as they can offer important insights.
Within the legal framework, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities as per Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and major hedge funds. These insiders are mandated to disclose their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
The initiation of a new purchase by a company insider serves as a strong indication that they expect the stock to rise.
However, insider sells may not always signal a bearish view and can be influenced by various factors.
<h3>Understanding Crucial Transaction Codes</h3>
When analyzing transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> tend to focus on those in the open market, detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase,while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001179929">Check Out The Full List Of Molina Healthcare's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Dale B Wolf Takes a Bullish Stance: Acquires $55K In Molina Healthcare Stock

Disclosed in the latest SEC filing, a significant insider purchase on January 2, involves Stephen H Lockhart, Board Member at Molina Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>).
What Happened: A Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0001179929/000117992925000017//Archives/edgar/data/1179929/000117992925000017/0001179929-25-000017-index.htm">U.S. Securities and Exchange Commission</a> on Thursday unveiled that Lockhart made a notable purchase of 189 shares of Molina Healthcare, valuing at $55,008.
In the Friday's morning session, Molina Healthcare's shares are currently trading at $287.24, experiencing a down of 0.0%.
<h3>Unveiling the Story Behind Molina Healthcare</h3>
Molina Healthcare Inc offers healthcare plans focused on Medicaid-related solutions for low-income families and individuals. Its health plans are operated by a network of subsidiaries, each of which is licensed as a health maintenance organization (HMO). It has four segments: Medicaid, Medicare, Marketplace and Others. The Medicaid, Medicare, and Marketplace segments represent the government-funded or sponsored programs under which it offers managed healthcare services. The Other segment, which is insignificant to its consolidated results of operations, includes long-term services and supports consultative services in Wisconsin. It generates majority revenue from Medicaid segment.
<h3>Molina Healthcare's Financial Performance</h3>
Revenue Growth: Molina Healthcare's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of 20.96%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Interpreting Earnings Metrics:
<ul>
<li>
Gross Margin: The company shows a low gross margin of 11.5%, indicating concerns regarding cost management and overall profitability relative to its industry counterparts.
</li>
<li>
Earnings per Share (EPS): Molina Healthcare's EPS is significantly higher than the industry average. The company demonstrates a robust bottom-line performance with a current EPS of 5.67.
</li>
</ul>
Debt Management: Molina Healthcare's debt-to-equity ratio surpasses industry norms, standing at 0.53. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
Navigating Market Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: The P/E ratio of 14.61 is lower than the industry average, implying a discounted valuation for Molina Healthcare's stock.
</li>
<li>
Price to Sales (P/S) Ratio: With a lower-than-average P/S ratio of 0.43, the stock presents an attractive valuation, potentially signaling a buying opportunity for investors interested in sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): With an EV/EBITDA ratio lower than industry averages at 5.34, Molina Healthcare could be considered undervalued.
</li>
</ul>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Why Insider Transactions Are Important</h3>
Insider transactions should be considered alongside other factors when making investment decisions, as they can offer important insights.
From a legal standpoint, the term "insider" pertains to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities as outlined in Section 12 of the Securities Exchange Act of 1934. This encompasses executives in the c-suite and significant hedge funds. These insiders are mandated to inform the public of their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
A company insider's new purchase is a indicator of their positive anticipation for a rise in the stock.
While insider sells may not necessarily reflect a bearish view and can be motivated by various factors.
<h3>Deciphering Transaction Codes in Insider Filings</h3>
Examining transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> often concentrate on those unfolding in the open market, meticulously detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C indicates the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001179929">Check Out The Full List Of Molina Healthcare's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Positive Signal: Stephen H Lockhart Shows Faith, Buying $55K In Molina Healthcare Stock

Molina Healthcare's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>) short percent of float has risen 8.29% since its last report. The company recently reported that it has 1.04 million shares sold short, which is 2.09% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.57 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Molina Healthcare Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1735573511_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Molina Healthcare has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Molina Healthcare's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Molina Healthcare's peer group average for short interest as a percentage of float is 5.65%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

How Is The Market Feeling About Molina Healthcare?

Molina Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>) has outperformed the market over the past 20 years by 3.64% on an annualized basis producing an average annual return of 11.93%. Currently, Molina Healthcare has a market capitalization of $16.85 billion. 
Buying $100 In MOH: If an investor had bought $100 of MOH stock 20 years ago, it would be worth $927.46 today based on a price of $294.50 for MOH at the time of writing.
<h3>Molina Healthcare's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1735049728_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In Molina Healthcare 20 Years Ago Would Be Worth This Much Today

Across the recent three months, 6 analysts have shared their insights on Molina Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>), expressing a variety of opinions spanning from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $371.17, with a high estimate of $406.00 and a low estimate of $331.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 3.76%. 
<img src="https://www.benzinga.com/files/images/story/2024/1734440483_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
The analysis of recent analyst actions sheds light on the perception of Molina Healthcare by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>John Stansel</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$350.00</td>
<td>$378.00</td>
</tr>
<tr>
<td>Stephen Baxter</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$362.00</td>
<td>$360.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$372.00</td>
<td>$359.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$406.00</td>
<td>$406.00</td>
</tr>
<tr>
<td>Michael Ha</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$331.00</td>
<td>$405.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$406.00</td>
<td>$406.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Molina Healthcare. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Molina Healthcare compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Molina Healthcare's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/MOH/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Molina Healthcare analyst ratings.</a>
<h2>Discovering Molina Healthcare: A Closer Look</h2>
Molina Healthcare Inc offers healthcare plans focused on Medicaid-related solutions for low-income families and individuals. Its health plans are operated by a network of subsidiaries, each of which is licensed as a health maintenance organization (HMO). It has four segments: Medicaid, Medicare, Marketplace and Others. The Medicaid, Medicare, and Marketplace segments represent the government-funded or sponsored programs under which it offers managed healthcare services. The Other segment, which is insignificant to its consolidated results of operations, includes long-term services and supports consultative services in Wisconsin. It generates majority revenue from Medicaid segment.
<h3>Molina Healthcare's Financial Performance</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Positive Revenue Trend: Examining Molina Healthcare's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 20.96% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 3.15%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Molina Healthcare's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 6.78% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Molina Healthcare's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 2.11% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Molina Healthcare's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.53.
<h2>Analyst Ratings: Simplified</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

The Analyst Verdict: Molina Healthcare In The Eyes Of 6 Experts

JP Morgan analyst John Stansel assumes Molina Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>) with a Neutral rating and lowers Price Target of $350.

Initiation

JP Morgan Assumes Molina Healthcare at Neutral, Lowers Price Target of $350

This new award follows the initial notice of intent to award the HIDE SNP contract announced by the MDHHS on October 9, 2024, and subsequently cancelled on November 8, 2024.&nbsp;
The go-live date for the new contract is expected to be January 1, 2026. The contract is expected to have a duration of seven years, with three one-year optional extensions.
 &nbsp;

Contracts

Molina Healthcare Bags Contract From Michigan Department Of Health And Human Services To Provide Dual Eligible Special Needs Plan; Also Secures Contract From Idaho Department Of Health And Welfare

Molina Healthcare's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>) short percent of float has fallen 24.26% since its last report. The company recently reported that it has 888 thousand shares sold short, which is 1.78% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.0 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Molina Healthcare Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732197622_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Molina Healthcare has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Molina Healthcare's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Molina Healthcare's peer group average for short interest as a percentage of float is 4.77%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Top U.S. health care mid-cap stocks and their Quant Ratings

Truist lowered the firm's price target on Molina Healthcare (MOH) to $370 from $400 and keeps a Buy rating on the shares as part of a broader resea...

Molina Healthcare price target lowered to $370 from $400 at Truist

Centers for Medicare & Medicaid Services will hold a call on Friday at 5pm to discuss Medicare Advantage and Part D and is expected to go over the ...

CMS likely to release 2026 MA rates Friday, says Wolfe Research

The Centers for Medicare & Medicaid Services, or CMS, released the Calendar Year 2026 Advance Notice for the Medicare Advantage, or MA, and the Med...

CMS expects 4.33% increase in Medicare Advantage rates in 2026

UnitedHealth posts rare quarterly miss amid rising medical expenses

UnitedHealth CEO: American healthcare needs to be "less complex and less confusing'

Molina Healthcare: Political Uncertainty Creates A Buying Opportunity

Elevance sends Medicaid insurers higher after Q4 revenue beat

In a memo dated January 27 from Matthew Vaeth, Acting Director, Office of Management and Budget, sent to the heads of the federal government's exec...

Medicaid insurers slip as Trump administration pauses assistance program payouts

Early Tuesday, the White House budget office circulated a 52-page document as it seeks to implement a sweeping freeze of federal assistance, orderi...

Medicare, Medicaid not impacted by Trump funding freeze, Politico reports

AMPH

ANIP

BMRN

CTKB

DOCS

ENOV

EXEL

Press Releases

Molina Healthcare Signs CEO Joe Zubretsky to New Employment Agreement

Molina Healthcare Senior Executive Vice President and CFO Mark Keim to Expand Role to Include Leadership of the Medicaid Health Plans and Marketplace Business

Molina Healthcare Announces Third Quarter 2024 Earnings Release and Conference Call Dates and Investor Day Meeting

Molina Healthcare Wins Michigan Contract to Provide a New Dual Eligible Benefit Program

Molina Healthcare Reports Third Quarter 2024 Financial Results

Molina Healthcare Announces Proposed Offering of $500 Million of Senior Notes Due 2033

Molina Healthcare Announces Pricing of $750 Million of 6.250% Senior Notes Due 2033

Molina Healthcare Announces Closing of Offering of $750 Million of 6.250% Senior Notes Due 2033

Molina Healthcare Awarded Contracts to Serve Dual Eligible Populations in Michigan and Idaho

Molina Healthcare Announces Fourth Quarter and Year-End 2024 Earnings Release and Conference Call Dates

Alignment Healthcare, Inc. - Common Stock

Alignment Healthcare

Clover Health Investments, Corp. - Class A Common stock

Clover Health Investments

Centene

Elevance Health

HealthEquity

Humana

NeueHealth

Progyny

UnitedHealth Group Incorporated Common Stock (DE)

UnitedHealth Group

Truist Securities

JP Morgan

Wells Fargo

Barclays

Cantor Fitzgerald

2008년 금융 위기를 예측한 것으로 유명한 헤지펀드 매니저인 마이클 버리(Michael Burry)는 2008년 금융 위기를 예측한 것으로 유명한 헤지펀드 매니저로, 최근 중국 기술 기업에 대한 노출을 크게 늘렸으며 동시에 잠재적 하방 위험에 대한 보호 조치를 시행했다고 <a href="https://www.benzinga.com/markets/asia/24/11/42000692/david-teppers-appaloosa-trims-alibaba-stake-by-476-in-q3-2024-doubles-down-on-pdd-holdings-and-jd.com">규제 공시</a>에서 밝혔다.
무슨 일이 있었나: 버리의 사이언 에셋 매니지먼트(Scion Asset Management)는 3분기 동안 포트폴리오에 몇 가지 주목할 만한 조정을 했으며, 이제 중국 기업들이 가장 큰 비중을 차지하고 있다. 이 회사는 알리바바 그룹 홀딩(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>)의 지분을 29% 늘려 9월 말 기준으로 2,100만 달러 이상의 가치로 펀드의 최대 보유 종목으로 만들었다.
비슷한 방식으로, 사이언은 JD닷컴(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JD#NASDAQ">JD</a>)의 지분을 두 배로 늘려 약 2,000만 달러로 펀드의 두 번째 대형 보유 종목으로 만들었다. 또한, 중국 검색 거대 기업인 바이두(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIDU#NASDAQ">BIDU</a>)에 대한 투자도 67% 증가시켜 1,320만 달러에 달했다.
하지만, 버리는 이러한 보유 종목에 대한 풋 옵션을 동시에 설정하여 조심스러운 전략을 취한 것으로 보인다. 풋 옵션은 기초 증권의 가치가 하락할 때 가치가 상승하는 경향이 있어, 시장 변동성에 대한 보호 전략으로 해석된다.
이러한 움직임은 베이징이 세계에서 두 번째로 큰 경제 성장률을 회복하기 위한 최근 경제 부양책 발표와 동시에 이루어졌다. 중국 주식은 이러한 신호가 나타난 후 9월에 처음으로 반등했지만, 투자자들이 더 구체적인 재정 조치를 기다리면서 상승폭은 완화되었다.
중국 기술 중심 외에도, 버리는 시프트4 페이먼츠(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FOUR#NYSE">FOUR</a>), 아메리칸 코스탈 인슈어런스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACIC#NASDAQ">ACIC</a>) 및 몰리나 헬스케어(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>)와 같은 여러 미국 기업에 대한 포지션도 늘렸다.
중요한 이유는: 버리의 <a href="https://www.benzinga.com/markets/equities/24/10/41248334/big-short-investor-michael-burrys-china-bet-pays-off-as-top-picks-surge-nearly-60-in-2-months">상위 세 개의 중국 보유 종목</a>은 두 달 동안 평균적으로 약 60%의 수익률을 기록했다고 한다.
버리의 움직임은 그의 트랙레코드를 고려할 때 시장 참여자들에 의해 면밀히 주시되고 있다. 그는 2008년 세계 금융 위기 이전에 모기지 담보 증권에 대한 선견지명이 있는 베팅으로 널리 알려졌으며, 이 이야기는 나중에 마이클 루이스의 베스트셀러 &#8220;빅 쇼트&#8221;와 그 후속 아카데미상 수상 영화로 기록되었다.
이러한 포지션은 9월 30일 기준으로 미 증권거래위원회(SEC) 규정에 따라 1억 달러 이상의 자산을 관리하는 펀드에 요구되는 보유 종목을 반영한다. 45일의 보고 지연과 버리의 적극적인 거래 스타일을 고려할 때, 현재 포지션은 이미 변경되었을 수 있다.
이러한 전개는 다른 <a href="https://www.benzinga.com/markets/asia/24/11/42000692/david-teppers-appaloosa-trims-alibaba-stake-by-476-in-q3-2024-doubles-down-on-pdd-holdings-and-jd.com">저명한 투자자들이 중국 보유 종목을 조정하는 것과</a> 동시에 일어났다. 억만장자 투자자 데이비드 테퍼의 아팔루사 매니지먼트는 최근 알리바바 지분을 5% 줄였지만, 여전히 펀드의 최대 보유 종목으로 67억 달러 포트폴리오의 15.75%를 차지하고 있다.

다음 읽기:
<ul>
<li><a href="https://www.benzinga.com/content/41999311/jim-cramer-says-these-10-frothy-stocks-are-up-over-200-ytd-including-rocket-lab-palantir-and-carvana">짐 크레이머가 올 해 200% 이상 상승한 &#8216;거품 주식&#8217; 10개를 언급하다: 로켓랩, 팔란티어, 카바나 포함</a></li>
</ul>
이미지 출처: Shutterstock
면책 조항:이 콘텐츠는 AI 도구의 도움으로 부분적으로 제작되었으며, 벤징가 편집자에 의해 검토 및 게시되었습니다.
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

'빅 쇼트' 투자자 마이클 버리, 중국 기술주에 베팅 확대하면서 보호 헤지 추가

이들 10개 대형주는 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요?
1. 테슬라(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>)의 주식은 실적 <a href="https://www.benzinga.com//node/41537560" target="_blank" rel="noreferrer noopener">호조와 전반적인 시장 강세</a>로 인해 21.97% 상승했다.
2. 리 오토(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LI#NASDAQ">LI</a>)의 주식은 중국 인민은행이 <a href="https://www.benzinga.com//node/41547149" target="_blank" rel="noreferrer noopener">7,000억 위안</a>($9,836억 달러)를 은행 시스템에 주입하고 금리를 2.0%로 유지한 후 14.02% 상승했다.
3. 몰리나 헬스케어(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>)의 주식은 회사가 <a href="https://www.benzinga.com//node/41500855" target="_blank" rel="noreferrer noopener">3분기 실적을 발표</a>한 후 12.36% 급등했다.
4. 태피스트리(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPR#NYSE">TPR</a>)의 주식은 자사의 카프리 홀딩스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPRI#NYSE">CPRI</a>) 인수 제안이 <a href="https://www.benzinga.com//node/41550527" target="_blank" rel="noreferrer noopener">법원에 의해 차단되었다는 보도</a> 이후 11.83% 상승했다. 이 회사는 이 결정에 대해 항소할 계획이라고 밝혔다.
5. 앱러빈(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APP#NASDAQ">APP</a>)의 주식은 여러 애널리스트들이 주가 전망을 <a href="https://www.benzinga.com/quote/APP/analyst-ratings" target="_blank" rel="noreferrer noopener">상향 조정한</a> 후 11.30% 상승했다.
6. 부즈 앨런 해밀턴 홀딩(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAH#NYSE">BAH</a>)의 주식은 2분기 재무 실적이 예상보다 좋게 나타나고 <a href="https://www.benzinga.com//node/41543105" target="_blank" rel="noreferrer noopener">2025 회계연도 가이던스가 강하게 나타난</a> 후 10.99% 상승했다.
7. 디지털 리얼티 트러스트(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DLR#NYSE">DLR</a>)의 주식은 3분기 FFO 실적이 예상보다 좋고 2024 회계연도 FFO 가이던스를 상향 조정한 후 9.45% 상승했다. 여러 애널리스트들이 주가 전망을 <a href="https://www.benzinga.com/quote/DLR/analyst-ratings" target="_blank" rel="noreferrer noopener">상향 조정</a>했다.
8. 그랩 홀딩스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRAB#NASDAQ">GRAB</a>)의 주식은 다이와 캐피털(Daiwa Capital)이 주식을 아웃퍼폼 등급으로 <a href="https://www.benzinga.com/quote/GRAB/analyst-ratings" target="_blank" rel="noreferrer noopener">커버리지 개시하고 $4.60의 목표 주가를 제시</a>한 후 9.12% 상승했다.
9. 마이크로스트레티지(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>)의 주식은 비트코인 가격 상승으로 <a href="https://www.benzinga.com//node/41544385" target="_blank" rel="noreferrer noopener">8.56% 상승</a>했다.
10. 필립 모리스 인터내셔널(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PM#NYSE">PM</a>)의 주식은 회사가 3분기 실적이 예상보다 좋게 나타나고 여러 애널리스트들이 목표 주가를 <a href="https://www.benzinga.com//node/41499153" target="_blank" rel="noreferrer noopener">상향 조정한</a> 후 8.03% 상승했다.
Photo via Shutterstock
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

이들 10개 대형주는 지난주 최악의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요?
1. 니오(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NIO#NYSE">NIO</a>)의 주식이 지난주 16.35% 하락했다. 이는 미국에 상장된 중국 주식들이 <a href="https://www.benzinga.com//node/41385461" target="_blank" rel="noreferrer noopener">중국의 9월 수출이 예상치를 밑돌면서</a> 하락한 후 발생한 일이다. 중국 경기 부양책에 대한 불확실성도 최근 주식에 악영향을 미쳤다.
2. KLA 코퍼레이션(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLAC#NASDAQ">KLAC</a>)의 주식이 지난주 15.58% 하락했다. 이는 ASML의 부진한 전망 발표 이후 지속적인 약세로 인한 것으로 보인다.
3. 센텐 코퍼레이션(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>)의 주식이 14.38% 하락했다. 이 회사는 <a href="https://www.benzinga.com/earnings" target="_blank" rel="noreferrer noopener">10월 25일 3분기 실적을 발표</a>할 예정이다.
4. 엘레반스 헬스(Elevance Health)의 주식이 14.17% 하락했다. 이는 분석가들이 <a href="https://www.benzinga.com//node/41405601" target="_blank" rel="noreferrer noopener">3분기 실적 발표 후 전망을 하향 조정한</a> 데 따른 것이다.
5. ASML 홀딩 N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASML#NASDAQ">ASML</a>)의 주식이 13.97% 하락했다. 회사가 실적 발표를 하루 일찍 실수로 공개하고 <a href="https://www.benzinga.com//node/41358875" target="_blank" rel="noreferrer noopener">2025년 매출 전망을 하향 조정한</a> 후 발생한 일이다.
6. PDD 홀딩스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDD#NASDAQ">PDD</a>)의 주식이 13.91% 하락했다. 이는 미국에 상장된 중국 주식들이 <a href="https://www.benzinga.com//node/41316058" target="_blank" rel="noreferrer noopener">중국의 9월 수출이 예상치를 밑돌면서</a> 하락한 것과 함께 발생한 일이다. 중국 경기 부양책에 대한 불확실성도 최근 주식에 악영향을 미쳤다.
7. 몰리나 헬스케어(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>)의 주식이 12.24% 하락했다. 이는 엘레반스 헬스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELV#NYSE">ELV</a>)와 동반 하락한 것으로 보인다. 엘레반스 헬스는 3분기 실적 부진과 2024년 전망을 낮춰 발표했다.
8. 램 리서치(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LRCX#NASDAQ">LRCX</a>)의 주식이 12.12% 하락했다. 이는 ASML의 부진한 전망 발표 이후 지속적인 약세로 인한 것으로 보인다.
9. 이리 인뎀니티(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ERIE#NASDAQ">ERIE</a>)의 주식이 지난주 9.92% 하락했다. 이는 스프루스 포인트 매니지먼트(Spruce Point Management)가 주식에 대한 <a href="https://www.sprucepointcap.com/research/erie-indemnity-company" target="_blank" rel="noreferrer noopener">공매도 보고서를 발표</a>한 후 발생한 일이다. 이 회사는 카테고리 5 허리케인 밀턴으로 압박을 받았다.
10. CVS 헬스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>)의 주식이 지난 주 9.44% 하락했다. 이 회사가 <a href="https://www.benzinga.com//node/41399396" target="_blank" rel="noreferrer noopener">3분기 전망을 하향 조정</a>한 후 발생한 일이다.
추가 읽기:
<ul>
<li><a href="https://kr.benzinga.com/news/usa/stocks/%EC%BD%94%EC%9D%B8%EB%B2%A0%EC%9D%B4%EC%8A%A4%EC%99%80-%EC%9C%A0%EB%82%98%EC%9D%B4%ED%8B%B0%EB%93%9C-%ED%95%AD%EA%B3%B5%EC%9D%80-%EC%A7%80%EB%82%9C%EC%A3%BC-%EC%B5%9C%EA%B3%A0-%EC%84%B1%EA%B3%BC/" target="_blank" rel="noopener">코인베이스, 유나이티드 항공 및 소파이 테크가 지난 주 가장 큰 대형주 상승 종목 중 하나 (10월 14-18일): 다른 종목들은 여러분의 포트폴리오에 포함되어 있나요?</a></li>
</ul>
사진 출처: Shutterstock
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

2008년 금융 위기 이전 주택 시장에 대한 선견지명 있는 투자로 유명한 유명 투자자 마이클 버리(Michael Burry)는 2024년 2분기에 자신의 헤지 펀드 포트폴리오에 큰 변화를 주었다.
어떤 일이 (What Happened): 사라토가에 본사를 두고 버리가 운영하는 사이언 에셋 매니지먼트(Scion Asset Management)는 수요일 미국 증권거래위원회(SEC)에 최신 13F 보고서를 제출하여 투자 전략의 주목할만한 변화를 밝혔다.
주요 포인트들은 다음과 같다:
<ol>
<li>알리바바 그룹 홀딩(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>)가 1위 자리를 차지함: 중국의 전자상거래 대기업인 알리바바는 155,000주로 구성된 약 1,116만 달러의 가치를 지닌 사이언의 최대 보유 기업이 되었다.</li>
<li>기술 초점: 이 포트폴리오는 중국 기술 기업들에 대한 지속적인 관심을 보여준다. 이에는 75,000주로 약 649만 달러의 가치를 형성하는 바이두(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIDU#NASDAQ">BIDU</a>)와 25만 주로 646만 달러의 가치를 형성하는 징동닷컴(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JD#NASDAQ">JD</a>)의 큰 비중이 포함되어 있다.</li>
<li>헬스케어 및 핀테크: 몰리나 헬스케어(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>)와 시프트4 페이먼츠(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FOUR#NYSE">FOUR</a>)는 각각 729만 달러와 734만 달러 상당의 상당한 투자를 보여준다.</li>
<li>부동산 노출: 허드슨 퍼시픽 프로퍼티즈(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HPP#NYSE">HPP</a>)는 550만 달러 상당의 주식 110만 주를 보유한 중요한 부동산 회사로 두각을 나타낸다.</li>
<li>바이오테크 신생기업: 임상 단계의 바이오제약 회사인 바이오아틀라(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCAB#NASDAQ">BCAB</a>)는 포트폴리오에서 작지만 주목할만한 위치를 나타낸다.</li>
</ol>
기타 주목할만한 보유 자산으로는 더 리얼리얼(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REAL#NASDAQ">REAL</a>), 올라플렉스 홀딩스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OLPX#NASDAQ">OLPX</a>), 그리고 아메리칸 코스탈 인슈어런스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACIC#NASDAQ">ACIC</a>)가 있다.
중요성 (Why It Matters): 이 최신 서류는 버리의 현재 시장 전망에 대한 통찰력을 제공하며 중국 기술 기업, 미국 의료, 핀테크 및 엄선된 부동산 기회에 대한 상당한 투자를 통한 다양한 접근 방식을 제안한다.
지난 5월 버리는 <a href="https://www.benzinga.com/markets/asia/24/05/38878116/big-short-investor-michael-burry-bets-heavy-on-gold-renewable-energy-stocks-exits-amazon-alphabet">금 및 신재생 에너지</a>에 대한 막대한 투자로 헤드라인을 장식했으며 아마존닷컴(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) 및 알파벳(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>)(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>)에서 포지션을 청산했다. 이 전환점은 실물 상품과 지속 가능한 에너지원에 초점을 맞추었음을 나타낸다.
관련해서, <a href="https://www.benzinga.com/general/entertainment/24/07/39695004/elon-musk-warren-buffett-nancy-pelosi-jensen-huang-michael-saylor-who-you-sitting-by-on-a-p">최근의 설문 조사</a>에서는 투자자들이 일론 머스크, 워런 버핏, Burry 자신과 같은 최고 인물들로부터 조언을 구하는 방법을 강조하여 투자 커뮤니티에서 그의 영향력을 강조한다.
Michael Burry illustration by Gonzalo Lanzilotta for
면책 조항: 본 콘텐츠는 인공지능 도구의 도움을 받아 제작되었으며, Benzinga 편집자들에 의해 검토되고 게시되었습니다.
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Asia

AMZN

BCAB

GOOG

GOOGL

OLPX

REAL

'빅쇼트' 명성의 마이클 버리, 중국에 큰 투자하고 알리바바를 최대 보유 주식으로 공개

이들 11개 대형주는 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요?
<ol>
<li>QXO(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QXO#NASDAQ">QXO</a>)의 주가는 <a href="https://www.benzinga.com//node/39880836" target="_blank" rel="noreferrer noopener">사모 금융 유치</a>를 발표한 이후 33.37% 상승했다.</li>
<li>아반토(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AVTR#NYSE">AVTR</a>)의 주식은 S&amp;P MidCap 400에 편입된다는 발표 이후 지난 주에 21.62% 상승했다. 또한 예상보다 나은 2분기 실적을 발표했다.</li>
<li>유니버셜 헬스 서비스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UHS#NYSE">UHS</a>)는 회사가 예상보다 나은 2분기 실적을 발표하고 <a href="https://www.benzinga.com//node/39942622" target="_blank" rel="noreferrer noopener">2024 회계연도 지침을</a> 상향 조정한 후 주가가 17.73% 상승했다.</li>
<li>맨하탄 어소시에이츠(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MANH#NASDAQ">MANH</a>)의 주가는 예상보다 나은 2분기 재무 결과를 보고한 후 17.02% 상승했다. 몇몇 분석가들은 주식에 대한 가격 <a href="https://www.benzinga.com/quote/MANH/analyst-ratings" target="_blank" rel="noreferrer noopener">예측</a>을 높였다.</li>
<li>몰리나 헬스케어(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>)의 주가는 <a href="https://www.benzinga.com//node/39942485" target="_blank" rel="noreferrer noopener">예상보다 좋은 2분기 실적</a>에 힘입어 15.53% 상승했다.</li>
<li>퍼스트 시티즌스 뱅크셰어스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FCNCA#NASDAQ">FCNCA</a>)의 주가는 회사의 분기 실적이 예상보다 높았음을 보고한 후 15.15% 상승했다.</li>
<li>테넷 헬스케어(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>)는 예상보다 나은 2분기 재무 결과를 보고한 후 주가가 13.02% 상승했으며, 회사는 FY24 지침을 추정치보다 높이고 3분기 지침을 추정치보다 높게 발표했다. 또한 회사는 <a href="https://www.benzinga.com//node/39934114" target="_blank" rel="noreferrer noopener">15억 달러 규모의</a> 자사주 매입을 승인했다고 발표했다.</li>
<li>CBRE 그룹(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CBRE#NYSE">CBRE</a>)은 회사가 2024년 목표를 상향 조정한 후 지난 주 주가가 12.99% 상승했다. 몇몇 분석가들은 주식에 대한 가격 <a href="https://www.benzinga.com/quote/MANH/analyst-ratings" target="_blank" rel="noreferrer noopener">예측</a>을 높였다.</li>
<li>써모 피셔 사이언티픽(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>)의 주가는 지난주 12.63% 상승했다. 이 회사는 연간 전망을 <a href="https://www.benzinga.com//node/39930516" target="_blank" rel="noreferrer noopener">상향 조정</a>했다.</li>
<li>다나허(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>)의 주가는 회사가 예상보다 나은 2분기 실적을 보고한 후 11.30% 상승하여 더 높게 거래되고 있다.</li>
<li>록히드 마틴(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LMT#NYSE">LMT</a>)의 주가는 긍정적인 애널리스트 <a href="https://www.benzinga.com//node/39941283" target="_blank" rel="noreferrer noopener">평가와 강한 2분기 실적</a>에 힘입어 10.72% 상승했다.</li>
</ol>
다음 기사:
<ul>
<li><a href="https://kr.benzinga.com/news/usa/stocks/%ed%8f%ac%eb%93%9c-%ec%8a%a4%ed%85%94%eb%9e%80%ed%8b%b0%ec%8a%a4-%eb%b0%8f-%eb%8d%b8%ec%9d%80-%ec%a7%80%eb%82%9c%ec%a3%bc-%ec%b5%9c%ec%95%85%ec%9d%98-%ec%84%b1%ea%b3%bc%eb%a5%bc-%eb%b3%b4%ec%9d%b8-12/" target="_blank" rel="noopener">포드, 스텔란티스 및 델은 지난주 최악의 성과를 보인 12개 대형주 중 일부 (7월 21일~7월 27일)</a></li>
</ul>
썸네일 제공: 셔터스톡
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Comments

Molina Healthcare

뉴스

에 대한 최신 뉴스 Molina Healthcare (NYSE:MOH) 주식

금요일, 11월 15, 2024

토요일, 10월 26, 2024

일요일, 10월 20, 2024

목요일, 8월 15, 2024

일요일, 7월 28, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌